Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ
Nat Rev Gastroenterol Hepatol 2020 Sep;17(9):557-588. Epub 2020 Jun 30 doi: 10.1038/s41575-020-0310-z. PMID: 32606456 Free PMC Article

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D
Nat Rev Gastroenterol Hepatol 2016 May;13(5):261-80. Epub 2016 Apr 20 doi: 10.1038/nrgastro.2016.51. PMID: 27095655

See all (19)

Recent clinical studies

Etiology

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group
Lancet Oncol 2023 Jul;24(7):772-782. Epub 2023 Jun 2 doi: 10.1016/S1470-2045(23)00242-5. PMID: 37276871

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14).

Lee CK, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, Kim MH, Park S, Kang B, Hong M, Kim JW, Park HS, Kang MJ, Park YN, Choi HJ
Lancet Gastroenterol Hepatol 2023 Jan;8(1):56-65. Epub 2022 Oct 31 doi: 10.1016/S2468-1253(22)00335-1. PMID: 36328033

Assessing the incidence of complications and malignancies in the long-term management of benign biliary strictures with a percutaneous transhepatic drain.

Yoshitomi M, Kawahara R, Taniwaki S, Midorikawa R, Kojima S, Muroya D, Arai S, Shirahama T, Kanno H, Fukutomi S, Goto Y, Nomura Y, Akashi M, Sato T, Sakai H, Hisaka T, Akagi Y
Medicine (Baltimore) 2022 Mar 11;101(10):e29048. doi: 10.1097/MD.0000000000029048. PMID: 35451417 Free PMC Article

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX
Lancet Oncol 2020 Jun;21(6):796-807. Epub 2020 May 13 doi: 10.1016/S1470-2045(20)30157-1. PMID: 32416072 Free PMC Article

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

See all (56)

Diagnosis

Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment.

Bragazzi MC, Venere R, Ribichini E, Covotta F, Cardinale V, Alvaro D
Dig Liver Dis 2024 Mar;56(3):383-393. Epub 2023 Sep 16 doi: 10.1016/j.dld.2023.08.052. PMID: 37722960

Regorafenib, an investigational agent for the treatment of cholangiocarcinoma.

Sahin IH, Tan E, Kim R
Expert Opin Investig Drugs 2021 Apr;30(4):333-341. Epub 2020 Dec 30 doi: 10.1080/13543784.2021.1867537. PMID: 33378249

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Genomic and transcriptional alterations of cholangiocarcinoma.

Ito T, Sakurai-Yageta M, Goto A, Pairojkul C, Yongvanit P, Murakami Y
J Hepatobiliary Pancreat Sci 2014 Jun;21(6):380-7. Epub 2014 Feb 13 doi: 10.1002/jhbp.67. PMID: 24532422

See all (49)

Therapy

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.

Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC
J Hepatol 2023 Dec;79(6):1450-1458. Epub 2023 Aug 28 doi: 10.1016/j.jhep.2023.08.017. PMID: 37647991

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.

Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492 Free PMC Article

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

See all (93)

Prognosis

Targeted therapies in advanced biliary tract cancers-a narrative review.

LaPelusa M, Heumann T, Goff L, Agarwal R
Chin Clin Oncol 2023 Apr;12(2):14. Epub 2023 Mar 13 doi: 10.21037/cco-22-93. PMID: 36946186 Free PMC Article

Assessing the incidence of complications and malignancies in the long-term management of benign biliary strictures with a percutaneous transhepatic drain.

The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.

Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN
Hepatology 2022 Feb;75(2):297-308. Epub 2021 Dec 6 doi: 10.1002/hep.32150. PMID: 34510503 Free PMC Article

Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract Carcinoma.

Saito Y, Muramatsu T, Kanai Y, Ojima H, Sukeda A, Hiraoka N, Arai E, Sugiyama Y, Matsuzaki J, Uchida R, Yoshikawa N, Furukawa R, Saito H
Cell Rep 2019 Apr 23;27(4):1265-1276.e4. doi: 10.1016/j.celrep.2019.03.088. PMID: 31018139

Radical resection combined with liver transplantation for foregut tumors.

Farmer DG, Shaked A, Colonna JO 2nd, Olthoff KM, Jurim O, Colquhoun S, Millis JM, Busuttil RW
Am Surg 1993 Dec;59(12):806-12. PMID: 8256933

See all (58)